Health insurance company Clover Health (NASDAQ: CLOV) will be reporting results tomorrow after market hours. Here’s what to look for.

Clover Health beat analysts’ revenue expectations last quarter, reporting revenues of $496.7 million, up 50.1% year on year. It was a slower quarter for the company, with full-year EBITDA guidance missing analysts’ expectations significantly and EPS in line with analysts’ estimates. It added 2,903 customers to reach a total of 109,226.

Is Clover Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Clover Health’s revenue to grow 38.6% year on year, improving from the 7.9% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Clover Health has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Clover Health’s peers in the health insurance providers segment, some have already reported their Q4 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.2%, beating analysts’ expectations by 2%, and Cigna reported revenues up 10.4%, topping estimates by 3.8%. CVS Health traded up 1.6% following the results while Cigna was also up 7.5%.

Read our full analysis of CVS Health’s results here and Cigna’s results here.

Investors in the health insurance providers segment have had fairly steady hands going into earnings, with share prices down 1.9% on average over the last month. Clover Health is down 14.8% during the same time and is heading into earnings with an average analyst price target of $3.23 (compared to the current share price of $2.01).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.